Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis

Launched by COSMETIQUE ACTIVE INTERNATIONAL · Nov 30, 2022

Keywords

ClinConnect Summary

The study is conducted in compliance, as closely as possible, with the current version of the world medical association declaration of Helsinki, local regulations based on International Council on Harmonisation (ICH) guidelines for Good Clinical Practice.

The primary objective of this study is to compare the tested emollient and the usual emollient through the weight of used dermocorticosteroid. The weight of used dermocorticosteroid is compared at the end of the study by a Student t-test (or a non parametric Wilcoxon test depending on the data distribution).

The following hypotheses are ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of atopic dermatitis must meet Hanifin's criteria (at least 3 basic features and at least 3 minor features)
• • mild atopic dermatitis present for at least 6 months before inclusion (SCORAD at inclusion between 20 and 30)
• • able to apply the emollient (each morning and evening) during a three-month period
• Exclusion Criteria:
• • presenting with another dermatological condition that could interfere with clinical evaluation
• • having received any systemic treatment, including PUVAtherapy for atopic dermatitis in the month prior to Day 0
• • who intend to expose themselves to the sun during the trial

Trial Officials